GlaxoSmithKline plc (GSK) Holdings Lifted by Fmr LLC

Fmr LLC grew its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 1.7% during the 3rd quarter, Holdings Channel reports. The firm owned 19,081,274 shares of the pharmaceutical company’s stock after buying an additional 327,721 shares during the period. Fmr LLC’s holdings in GlaxoSmithKline were worth $766,495,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Optimum Investment Advisors increased its position in shares of GlaxoSmithKline by 88.5% during the 3rd quarter. Optimum Investment Advisors now owns 2,749 shares of the pharmaceutical company’s stock worth $110,000 after purchasing an additional 1,291 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of GlaxoSmithKline during the 2nd quarter worth approximately $134,000. Toronto Dominion Bank increased its position in shares of GlaxoSmithKline by 46.0% during the 2nd quarter. Toronto Dominion Bank now owns 4,600 shares of the pharmaceutical company’s stock worth $186,000 after purchasing an additional 1,450 shares during the last quarter. Whitener Capital Management Inc. acquired a new position in shares of GlaxoSmithKline during the 3rd quarter worth approximately $185,000. Finally, Amussen Hunsaker Associates LLC acquired a new position in shares of GlaxoSmithKline during the 2nd quarter worth approximately $193,000. 10.87% of the stock is currently owned by hedge funds and other institutional investors.

GSK stock opened at $40.66 on Friday. The company has a current ratio of 0.95, a quick ratio of 0.63 and a debt-to-equity ratio of 6.66. The company has a market cap of $100.83 billion, a P/E ratio of 14.12, a price-to-earnings-growth ratio of 2.73 and a beta of 0.80. GlaxoSmithKline plc has a 1-year low of $34.52 and a 1-year high of $42.36.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 31st. The pharmaceutical company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.03). GlaxoSmithKline had a net margin of 5.78% and a return on equity of 164.99%. The firm had revenue of $9.41 billion during the quarter, compared to analyst estimates of $10.55 billion. Equities analysts forecast that GlaxoSmithKline plc will post 2.98 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 10th. Shareholders of record on Friday, November 16th will be issued a $0.486 dividend. This represents a $1.94 dividend on an annualized basis and a yield of 4.78%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.46. The ex-dividend date is Thursday, November 15th. GlaxoSmithKline’s dividend payout ratio is currently 67.36%.

GSK has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, September 25th. Wolfe Research initiated coverage on GlaxoSmithKline in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Tuesday, September 25th. ValuEngine raised GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Friday, October 19th. Finally, Liberum Capital lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, August 30th. Eleven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $41.57.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Holdings Lifted by Fmr LLC” was posted by WKRB News and is the property of of WKRB News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.wkrb13.com/2018/11/25/glaxosmithkline-plc-gsk-holdings-lifted-by-fmr-llc.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: Market Capitalization and Individual Investors

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply